BioCentury | Aug 22, 2020
Management Tracks

Qiagen chairman steps down, plus changes at Sanifit and Xeris

...By Elizabeth s. eaton, Staff Writer Qiagen N.V. (NYSE:QGEN; Xetra:QIA) Chairman Håkan Björklund has stepped down, a week...
...company Xeris Pharmaceuticals Inc. (NASDAQ:XERS) has promoted COO John Shannon to president and COO. Elizabeth S. Eaton Qiagen N.V. Laboratoris...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...By Biocentury staff Qiagen to remain independentQiagen N.V. (NYSE:QGEN; Xetra:QIA) said it terminated its agreement to...
...acquired by Thermo Fisher Scientific Inc. (NYSE:TMO) after only 47% of shares were tendered by Qiagen...
...diagnostics company for €39 ($43.33) per share, or about $11.5 billion (see “Thermo Fisher Takes out Qiagen”).Inhibrx, Harmony near...
BioCentury | Jun 26, 2020
Politics, Policy & Law

Illumina, BGI litigation not yet at risk of getting drawn into U.S.-China dispute

...compare the nature of the lawsuits between Illumina and BGI and that between Illumina and Qiagen...
...BGI. Since 2012, Illumina has had an ongoing patent dispute with its largest European competitor, Qiagen N.V....
...compare the nature of the lawsuits between Illumina and BGI and that between Illumina and Qiagen...
BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

...FDA’s emergency use authorization for a Qiagen test Tuesday comes amid a flurry of advancements in...
...GigaGen’s unveiling of a polyclonal antibody program derived from convalescent COVID-19 patients. The test from Qiagen N.V....
...choice. Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor Qiagen N.V. Becton...
BioCentury | Mar 31, 2020
Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

...for €360 million in milestones. It also invested in Stat-Dx Life S.L., a diagnostics company Qiagen N.V....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen...
...to provide diagnostic testing during the COVID-19 pandemic. Thermo Fisher Scientific Inc. (NYSE:TMO) is acquiring Qiagen...
...is retiring April 30. Reali was president and CEO of Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX...
BioCentury | Mar 17, 2020
Product Development

FDA expanding U.S. COVID-19 test capacity, industry ramping up to meet demand

...Authorizations to expand COVID-19 test capacity. Diagnostics companies are also stepping up to meet demand. Qiagen...
...basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.” Industry ramping up Qiagen N.V....
...around the world to detect nucleic acid from SARS-CoV-2, the novel coronavirus that causes COVID-19.” Qiagen...
BioCentury | Mar 13, 2020
Politics, Policy & Law

U.S. moves to unlock COVID-19 test capacity

...Qiagen, DiaSorin tests HHS’s Biomedical Advanced Research and Development Authority is funding development efforts at Qiagen N.V....
...DiaSorin could submit its rapid COVID-19 test for EUA within six weeks, BARDA said, while Qiagen’s...
...NYSE:TMO) is acquiring Qiagen in a deal announced March 3 (see “ Thermo Takes Out Qiagen...
BioCentury | Mar 10, 2020
Finance

Diagnostics companies survive Monday’s market rout

...slipped 5% Monday, losing $15.82 to $295.35. The lab tools company is set to acquire Qiagen N.V....
...has developed a COVID-19 diagnostic, for $11.5 billion (see “Thermo Fisher Takes out Qiagen” ). Qiagen...
BioCentury | Mar 4, 2020
Deals

Thermo Fisher takes out Qiagen for $11.5B

...acquiring Qiagen N.V. (NYSE:QGEN; Xetra:QIA) for €39 ($43.33) per share, which is a 21% premium over Qiagen’s...
...complements Thermo Fisher’s genetic analysis and biosciences capabilities. Qiagen had 2019 revenues of $1.5 billion. Qiagen...
...that can test for the presence of SARS-CoV-2 (see “Qiagen Ships Diagnostic to China” ). Qiagen...
Items per page:
1 - 10 of 746
BioCentury | Aug 22, 2020
Management Tracks

Qiagen chairman steps down, plus changes at Sanifit and Xeris

...By Elizabeth s. eaton, Staff Writer Qiagen N.V. (NYSE:QGEN; Xetra:QIA) Chairman Håkan Björklund has stepped down, a week...
...company Xeris Pharmaceuticals Inc. (NASDAQ:XERS) has promoted COO John Shannon to president and COO. Elizabeth S. Eaton Qiagen N.V. Laboratoris...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...By Biocentury staff Qiagen to remain independentQiagen N.V. (NYSE:QGEN; Xetra:QIA) said it terminated its agreement to...
...acquired by Thermo Fisher Scientific Inc. (NYSE:TMO) after only 47% of shares were tendered by Qiagen...
...diagnostics company for €39 ($43.33) per share, or about $11.5 billion (see “Thermo Fisher Takes out Qiagen”).Inhibrx, Harmony near...
BioCentury | Jun 26, 2020
Politics, Policy & Law

Illumina, BGI litigation not yet at risk of getting drawn into U.S.-China dispute

...compare the nature of the lawsuits between Illumina and BGI and that between Illumina and Qiagen...
...BGI. Since 2012, Illumina has had an ongoing patent dispute with its largest European competitor, Qiagen N.V....
...compare the nature of the lawsuits between Illumina and BGI and that between Illumina and Qiagen...
BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

...FDA’s emergency use authorization for a Qiagen test Tuesday comes amid a flurry of advancements in...
...GigaGen’s unveiling of a polyclonal antibody program derived from convalescent COVID-19 patients. The test from Qiagen N.V....
...choice. Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor Qiagen N.V. Becton...
BioCentury | Mar 31, 2020
Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

...for €360 million in milestones. It also invested in Stat-Dx Life S.L., a diagnostics company Qiagen N.V....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen...
...to provide diagnostic testing during the COVID-19 pandemic. Thermo Fisher Scientific Inc. (NYSE:TMO) is acquiring Qiagen...
...is retiring April 30. Reali was president and CEO of Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX...
BioCentury | Mar 17, 2020
Product Development

FDA expanding U.S. COVID-19 test capacity, industry ramping up to meet demand

...Authorizations to expand COVID-19 test capacity. Diagnostics companies are also stepping up to meet demand. Qiagen...
...basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.” Industry ramping up Qiagen N.V....
...around the world to detect nucleic acid from SARS-CoV-2, the novel coronavirus that causes COVID-19.” Qiagen...
BioCentury | Mar 13, 2020
Politics, Policy & Law

U.S. moves to unlock COVID-19 test capacity

...Qiagen, DiaSorin tests HHS’s Biomedical Advanced Research and Development Authority is funding development efforts at Qiagen N.V....
...DiaSorin could submit its rapid COVID-19 test for EUA within six weeks, BARDA said, while Qiagen’s...
...NYSE:TMO) is acquiring Qiagen in a deal announced March 3 (see “ Thermo Takes Out Qiagen...
BioCentury | Mar 10, 2020
Finance

Diagnostics companies survive Monday’s market rout

...slipped 5% Monday, losing $15.82 to $295.35. The lab tools company is set to acquire Qiagen N.V....
...has developed a COVID-19 diagnostic, for $11.5 billion (see “Thermo Fisher Takes out Qiagen” ). Qiagen...
BioCentury | Mar 4, 2020
Deals

Thermo Fisher takes out Qiagen for $11.5B

...acquiring Qiagen N.V. (NYSE:QGEN; Xetra:QIA) for €39 ($43.33) per share, which is a 21% premium over Qiagen’s...
...complements Thermo Fisher’s genetic analysis and biosciences capabilities. Qiagen had 2019 revenues of $1.5 billion. Qiagen...
...that can test for the presence of SARS-CoV-2 (see “Qiagen Ships Diagnostic to China” ). Qiagen...
Items per page:
1 - 10 of 746